The pharmacology of atracurium: a new competitive neuromuscular blocking agent.

  title={The pharmacology of atracurium: a new competitive neuromuscular blocking agent.},
  author={R. Hughes and D. J. Chapple},
  journal={British journal of anaesthesia},
  volume={53 1},
  • R. Hughes, D. J. Chapple
  • Published 1981
  • Medicine
  • British journal of anaesthesia
  • Atracurium besylate, 2,2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-[6,7-dimethoxy-1-(3,4-dimethoxy-benzyl)-2-methyl-1,2,3,4-tetrahydroisoquinolinium] dibenzenesulphonate, is one of a new series of competitive neuromuscular blocking agents. An i.v. dose of 0.25 mg kg-1 produced complete paralysis in anaesthetized cats, dogs and rhesus monkeys; paralysis was of medium duration and was readily antagonized by neostigmine. Vagal blockade occurred only after doses 8--16 times greater than the full… CONTINUE READING
    172 Citations
    Evaluation of atracurium in anaesthetized man.
    • 158
    • PDF
    Clinical Pharmacology of Atracurium Besylate (BW 33A): A New Non‐depolarizing Muscle Relaxant
    • 157
    • Highly Influenced
    Newer Neuromuscular Blocking Agents
    • 16
    Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH.
    • 24


    Studies on fazadinium bromide (AH 8165): A new non-depolarizing neuromuscular blocking agent
    • 10
    • PDF
    Studies on dimethyl tubocurarine in anaesthetized man.
    • 20
    Clinical Pharmacokinetics of Muscle Relaxants
    • 19
    The influence of changes in acid-base balance on neuromuscular blockade in cats.
    • R. Hughes
    • Medicine
    • British journal of anaesthesia
    • 1970
    • 22
    • PDF